CD44 and cancer: Several groups, including ours, have demonstrated that the presence of cancer stem-like cells (CSC) in tumors displaying mesenchymal phenotypes (epithelial-to-mesenchymal transdifferentiation, EMT) and CD44+/CD133+ cells, with self-renewal and differentiation capacities, play crucial roles in tumor progression and development of mCRPC (13–16).